Loading…

Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments

The brain has a unique biological complexity and is responsible for important functions in the human body, such as the command of cognitive and motor functions. Disruptive disorders that affect this organ, e.g. neurodegenerative diseases (NDDs), can lead to permanent damage, impairing the patients&#...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2019-04, Vol.20 (8), p.1829
Main Authors: Sales, Thais A, Prandi, Ingrid G, Castro, Alexandre A de, Leal, Daniel H S, Cunha, Elaine F F da, Kuca, Kamil, Ramalho, Teodorico C
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c478t-1af67c396b6ab0c98ac21295fdd5502bfef2bf83a948c879efd1bcf2e4080c803
cites cdi_FETCH-LOGICAL-c478t-1af67c396b6ab0c98ac21295fdd5502bfef2bf83a948c879efd1bcf2e4080c803
container_end_page
container_issue 8
container_start_page 1829
container_title International journal of molecular sciences
container_volume 20
creator Sales, Thais A
Prandi, Ingrid G
Castro, Alexandre A de
Leal, Daniel H S
Cunha, Elaine F F da
Kuca, Kamil
Ramalho, Teodorico C
description The brain has a unique biological complexity and is responsible for important functions in the human body, such as the command of cognitive and motor functions. Disruptive disorders that affect this organ, e.g. neurodegenerative diseases (NDDs), can lead to permanent damage, impairing the patients' quality of life and even causing death. In spite of their clinical diversity, these NDDs share common characteristics, such as the accumulation of specific proteins in the cells, the compromise of the metal ion homeostasis in the brain, among others. Despite considerable advances in understanding the mechanisms of these diseases and advances in the development of treatments, these disorders remain uncured. Considering the diversity of mechanisms that act in NDDs, a wide range of compounds have been developed to act by different means. Thus, promising compounds with contrasting properties, such as chelating agents and metal-based drugs have been proposed to act on different molecular targets as well as to contribute to the same goal, which is the treatment of NDDs. This review seeks to discuss the different roles and recent developments of metal-based drugs, such as metal complexes and metal chelating agents as a proposal for the treatment of NDDs.
doi_str_mv 10.3390/ijms20081829
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a1624ec9718c43cca3835c08cb717770</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a1624ec9718c43cca3835c08cb717770</doaj_id><sourcerecordid>2332333391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-1af67c396b6ab0c98ac21295fdd5502bfef2bf83a948c879efd1bcf2e4080c803</originalsourceid><addsrcrecordid>eNpdks2L1DAUwIso7rp68ywBLx6s5qNtkouwzvixsCrIeg6v6Us3Q9uMSTvgf29mZl1mhZCE9375kby8onjJ6DshNH3vN2PilCqmuH5UnLOK85LSRj4-2Z8Vz1LaUMoFr_XT4kwwyoSqm_Oi_4kWp5mscYdD2I55n4ifyDecYSg_QsKOrOPSJwJTR1a3OMDsp55c9gfShUi-4xJDhzmAMSd3SNY-YT6ZyE1EmA_O58UTB0PCF3frRfHr86eb1dfy-seXq9XldWkrqeaSgWukFbppG2ip1QosZ1zXruvqmvLWocuTEqArZZXU6DrWWsexoopaRcVFcXX0dgE2Zhv9CPGPCeDNIRBibyDO3g5ogDW8QqslU7YS1oJQorZU2VYyKeXe9eHo2i7tiN2-ThGGB9KHmcnfmj7sTFOzSkqVBW_uBDH8XjDNZvTJ4jDAhGFJhnMmNNeaVhl9_R-6CUuccqkMFyKP_NcsU2-PlI0hpYju_jKMmn03mNNuyPir0wfcw_--X_wFfGexjQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2332333391</pqid></control><display><type>article</type><title>Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Sales, Thais A ; Prandi, Ingrid G ; Castro, Alexandre A de ; Leal, Daniel H S ; Cunha, Elaine F F da ; Kuca, Kamil ; Ramalho, Teodorico C</creator><creatorcontrib>Sales, Thais A ; Prandi, Ingrid G ; Castro, Alexandre A de ; Leal, Daniel H S ; Cunha, Elaine F F da ; Kuca, Kamil ; Ramalho, Teodorico C</creatorcontrib><description>The brain has a unique biological complexity and is responsible for important functions in the human body, such as the command of cognitive and motor functions. Disruptive disorders that affect this organ, e.g. neurodegenerative diseases (NDDs), can lead to permanent damage, impairing the patients' quality of life and even causing death. In spite of their clinical diversity, these NDDs share common characteristics, such as the accumulation of specific proteins in the cells, the compromise of the metal ion homeostasis in the brain, among others. Despite considerable advances in understanding the mechanisms of these diseases and advances in the development of treatments, these disorders remain uncured. Considering the diversity of mechanisms that act in NDDs, a wide range of compounds have been developed to act by different means. Thus, promising compounds with contrasting properties, such as chelating agents and metal-based drugs have been proposed to act on different molecular targets as well as to contribute to the same goal, which is the treatment of NDDs. This review seeks to discuss the different roles and recent developments of metal-based drugs, such as metal complexes and metal chelating agents as a proposal for the treatment of NDDs.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms20081829</identifier><identifier>PMID: 31013856</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Age ; Amyloid - chemistry ; Amyloid - metabolism ; Amyloid beta-Peptides - chemistry ; Amyloid beta-Peptides - metabolism ; Amyotrophic lateral sclerosis ; Animals ; Chelating agents ; Chelating Agents - chemistry ; Chelating Agents - pharmacology ; Chelating Agents - therapeutic use ; Chelation ; Dementia ; Dementia disorders ; Disease ; Drug Development ; Drug Repositioning ; Drugs ; Enzymes ; Humans ; Hypotheses ; metallodrugs ; Metals - chemistry ; Metals - metabolism ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Neurodegeneration ; Neurodegenerative Diseases - drug therapy ; Neurodegenerative Diseases - etiology ; Neurodegenerative Diseases - metabolism ; Neurodegenerative Diseases - pathology ; Older people ; Patients ; Peptides ; Population ; Proteins ; Review ; Roles ; Signs and symptoms ; Structure-Activity Relationship</subject><ispartof>International journal of molecular sciences, 2019-04, Vol.20 (8), p.1829</ispartof><rights>2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-1af67c396b6ab0c98ac21295fdd5502bfef2bf83a948c879efd1bcf2e4080c803</citedby><cites>FETCH-LOGICAL-c478t-1af67c396b6ab0c98ac21295fdd5502bfef2bf83a948c879efd1bcf2e4080c803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2332333391/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2332333391?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31013856$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sales, Thais A</creatorcontrib><creatorcontrib>Prandi, Ingrid G</creatorcontrib><creatorcontrib>Castro, Alexandre A de</creatorcontrib><creatorcontrib>Leal, Daniel H S</creatorcontrib><creatorcontrib>Cunha, Elaine F F da</creatorcontrib><creatorcontrib>Kuca, Kamil</creatorcontrib><creatorcontrib>Ramalho, Teodorico C</creatorcontrib><title>Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>The brain has a unique biological complexity and is responsible for important functions in the human body, such as the command of cognitive and motor functions. Disruptive disorders that affect this organ, e.g. neurodegenerative diseases (NDDs), can lead to permanent damage, impairing the patients' quality of life and even causing death. In spite of their clinical diversity, these NDDs share common characteristics, such as the accumulation of specific proteins in the cells, the compromise of the metal ion homeostasis in the brain, among others. Despite considerable advances in understanding the mechanisms of these diseases and advances in the development of treatments, these disorders remain uncured. Considering the diversity of mechanisms that act in NDDs, a wide range of compounds have been developed to act by different means. Thus, promising compounds with contrasting properties, such as chelating agents and metal-based drugs have been proposed to act on different molecular targets as well as to contribute to the same goal, which is the treatment of NDDs. This review seeks to discuss the different roles and recent developments of metal-based drugs, such as metal complexes and metal chelating agents as a proposal for the treatment of NDDs.</description><subject>Age</subject><subject>Amyloid - chemistry</subject><subject>Amyloid - metabolism</subject><subject>Amyloid beta-Peptides - chemistry</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Amyotrophic lateral sclerosis</subject><subject>Animals</subject><subject>Chelating agents</subject><subject>Chelating Agents - chemistry</subject><subject>Chelating Agents - pharmacology</subject><subject>Chelating Agents - therapeutic use</subject><subject>Chelation</subject><subject>Dementia</subject><subject>Dementia disorders</subject><subject>Disease</subject><subject>Drug Development</subject><subject>Drug Repositioning</subject><subject>Drugs</subject><subject>Enzymes</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>metallodrugs</subject><subject>Metals - chemistry</subject><subject>Metals - metabolism</subject><subject>Molecular Docking Simulation</subject><subject>Molecular Dynamics Simulation</subject><subject>Neurodegeneration</subject><subject>Neurodegenerative Diseases - drug therapy</subject><subject>Neurodegenerative Diseases - etiology</subject><subject>Neurodegenerative Diseases - metabolism</subject><subject>Neurodegenerative Diseases - pathology</subject><subject>Older people</subject><subject>Patients</subject><subject>Peptides</subject><subject>Population</subject><subject>Proteins</subject><subject>Review</subject><subject>Roles</subject><subject>Signs and symptoms</subject><subject>Structure-Activity Relationship</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdks2L1DAUwIso7rp68ywBLx6s5qNtkouwzvixsCrIeg6v6Us3Q9uMSTvgf29mZl1mhZCE9375kby8onjJ6DshNH3vN2PilCqmuH5UnLOK85LSRj4-2Z8Vz1LaUMoFr_XT4kwwyoSqm_Oi_4kWp5mscYdD2I55n4ifyDecYSg_QsKOrOPSJwJTR1a3OMDsp55c9gfShUi-4xJDhzmAMSd3SNY-YT6ZyE1EmA_O58UTB0PCF3frRfHr86eb1dfy-seXq9XldWkrqeaSgWukFbppG2ip1QosZ1zXruvqmvLWocuTEqArZZXU6DrWWsexoopaRcVFcXX0dgE2Zhv9CPGPCeDNIRBibyDO3g5ogDW8QqslU7YS1oJQorZU2VYyKeXe9eHo2i7tiN2-ThGGB9KHmcnfmj7sTFOzSkqVBW_uBDH8XjDNZvTJ4jDAhGFJhnMmNNeaVhl9_R-6CUuccqkMFyKP_NcsU2-PlI0hpYju_jKMmn03mNNuyPir0wfcw_--X_wFfGexjQ</recordid><startdate>20190412</startdate><enddate>20190412</enddate><creator>Sales, Thais A</creator><creator>Prandi, Ingrid G</creator><creator>Castro, Alexandre A de</creator><creator>Leal, Daniel H S</creator><creator>Cunha, Elaine F F da</creator><creator>Kuca, Kamil</creator><creator>Ramalho, Teodorico C</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190412</creationdate><title>Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments</title><author>Sales, Thais A ; Prandi, Ingrid G ; Castro, Alexandre A de ; Leal, Daniel H S ; Cunha, Elaine F F da ; Kuca, Kamil ; Ramalho, Teodorico C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-1af67c396b6ab0c98ac21295fdd5502bfef2bf83a948c879efd1bcf2e4080c803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Age</topic><topic>Amyloid - chemistry</topic><topic>Amyloid - metabolism</topic><topic>Amyloid beta-Peptides - chemistry</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Amyotrophic lateral sclerosis</topic><topic>Animals</topic><topic>Chelating agents</topic><topic>Chelating Agents - chemistry</topic><topic>Chelating Agents - pharmacology</topic><topic>Chelating Agents - therapeutic use</topic><topic>Chelation</topic><topic>Dementia</topic><topic>Dementia disorders</topic><topic>Disease</topic><topic>Drug Development</topic><topic>Drug Repositioning</topic><topic>Drugs</topic><topic>Enzymes</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>metallodrugs</topic><topic>Metals - chemistry</topic><topic>Metals - metabolism</topic><topic>Molecular Docking Simulation</topic><topic>Molecular Dynamics Simulation</topic><topic>Neurodegeneration</topic><topic>Neurodegenerative Diseases - drug therapy</topic><topic>Neurodegenerative Diseases - etiology</topic><topic>Neurodegenerative Diseases - metabolism</topic><topic>Neurodegenerative Diseases - pathology</topic><topic>Older people</topic><topic>Patients</topic><topic>Peptides</topic><topic>Population</topic><topic>Proteins</topic><topic>Review</topic><topic>Roles</topic><topic>Signs and symptoms</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sales, Thais A</creatorcontrib><creatorcontrib>Prandi, Ingrid G</creatorcontrib><creatorcontrib>Castro, Alexandre A de</creatorcontrib><creatorcontrib>Leal, Daniel H S</creatorcontrib><creatorcontrib>Cunha, Elaine F F da</creatorcontrib><creatorcontrib>Kuca, Kamil</creatorcontrib><creatorcontrib>Ramalho, Teodorico C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep (ProQuest)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sales, Thais A</au><au>Prandi, Ingrid G</au><au>Castro, Alexandre A de</au><au>Leal, Daniel H S</au><au>Cunha, Elaine F F da</au><au>Kuca, Kamil</au><au>Ramalho, Teodorico C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2019-04-12</date><risdate>2019</risdate><volume>20</volume><issue>8</issue><spage>1829</spage><pages>1829-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>The brain has a unique biological complexity and is responsible for important functions in the human body, such as the command of cognitive and motor functions. Disruptive disorders that affect this organ, e.g. neurodegenerative diseases (NDDs), can lead to permanent damage, impairing the patients' quality of life and even causing death. In spite of their clinical diversity, these NDDs share common characteristics, such as the accumulation of specific proteins in the cells, the compromise of the metal ion homeostasis in the brain, among others. Despite considerable advances in understanding the mechanisms of these diseases and advances in the development of treatments, these disorders remain uncured. Considering the diversity of mechanisms that act in NDDs, a wide range of compounds have been developed to act by different means. Thus, promising compounds with contrasting properties, such as chelating agents and metal-based drugs have been proposed to act on different molecular targets as well as to contribute to the same goal, which is the treatment of NDDs. This review seeks to discuss the different roles and recent developments of metal-based drugs, such as metal complexes and metal chelating agents as a proposal for the treatment of NDDs.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>31013856</pmid><doi>10.3390/ijms20081829</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2019-04, Vol.20 (8), p.1829
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a1624ec9718c43cca3835c08cb717770
source Open Access: PubMed Central; Publicly Available Content Database
subjects Age
Amyloid - chemistry
Amyloid - metabolism
Amyloid beta-Peptides - chemistry
Amyloid beta-Peptides - metabolism
Amyotrophic lateral sclerosis
Animals
Chelating agents
Chelating Agents - chemistry
Chelating Agents - pharmacology
Chelating Agents - therapeutic use
Chelation
Dementia
Dementia disorders
Disease
Drug Development
Drug Repositioning
Drugs
Enzymes
Humans
Hypotheses
metallodrugs
Metals - chemistry
Metals - metabolism
Molecular Docking Simulation
Molecular Dynamics Simulation
Neurodegeneration
Neurodegenerative Diseases - drug therapy
Neurodegenerative Diseases - etiology
Neurodegenerative Diseases - metabolism
Neurodegenerative Diseases - pathology
Older people
Patients
Peptides
Population
Proteins
Review
Roles
Signs and symptoms
Structure-Activity Relationship
title Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T22%3A52%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20Developments%20in%20Metal-Based%20Drugs%20and%20Chelating%20Agents%20for%20Neurodegenerative%20Diseases%20Treatments&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Sales,%20Thais%20A&rft.date=2019-04-12&rft.volume=20&rft.issue=8&rft.spage=1829&rft.pages=1829-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms20081829&rft_dat=%3Cproquest_doaj_%3E2332333391%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-1af67c396b6ab0c98ac21295fdd5502bfef2bf83a948c879efd1bcf2e4080c803%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2332333391&rft_id=info:pmid/31013856&rfr_iscdi=true